Interstitial Lung Disease: A Complete Guide to the Family of Conditions That Scar the Lungs
You have been told you have "interstitial lung disease" — or "scarring on the lungs" — and you do not fully understand what that means, what caused it, or what happens next. A pulmonologist explains the full ILD spectrum, why getting the specific diagnosis right is critical, and what modern treatment looks like for each type.
She came in holding a CT scan report that used the words "interstitial changes" and "ground-glass opacities" — and she had spent the previous two weeks searching these terms online, reading everything from reassuring forum posts to terrifying descriptions of rapidly progressive fibrosis. She did not know whether her condition was treatable or incurable, whether it would progress or stabilise, whether the cause was something in her environment or something in her body, or whether the medication she had been started on was the right one. She knew only that something was happening in her lungs that nobody had yet properly explained to her.
This experience — receiving an ILD diagnosis or finding ILD-related findings on a scan without adequate explanation — is common, and it generates enormous unnecessary anxiety. "Interstitial lung disease" is not a single condition. It is an umbrella term for more than 200 different conditions that affect the interstitium — the tissue framework of the lung surrounding the air sacs. Some are self-limiting. Some respond dramatically to treatment. Some progress slowly over decades. Some require aggressive management to prevent rapid deterioration. The treatment, prognosis, and follow-up plan for each type differ substantially — and these differences make accurate specific diagnosis the single most important step in ILD management.
This article provides a comprehensive map of the ILD landscape — what unites these conditions, what distinguishes them from each other, how the correct diagnosis is reached, and what treatment looks like across the ILD spectrum.
What Is Interstitial Lung Disease?
To understand ILD, it helps to understand the anatomy it affects. The lung is not simply a bag filled with air. It is a complex three-dimensional tissue scaffold — the interstitium — through which the airways and blood vessels run and on which the air sacs (alveoli) are built. The interstitium provides structural support, houses the immune cells that defend against pathogens and regulate inflammation, and maintains the delicate membrane across which oxygen and carbon dioxide are exchanged between the air sacs and the blood vessels.
Interstitial lung diseases are conditions in which this tissue framework is damaged — by inflammation, by the accumulation of abnormal cells or material, or by the replacement of normal tissue with scar tissue (fibrosis). As the interstitium thickens and stiffens, the lungs lose their normal elasticity and compliance, the distance across which oxygen must diffuse into the blood vessels increases, and respiratory function progressively deteriorates. The result is a characteristic pattern — a restrictive pattern on spirometry, reduced gas transfer on DLCO testing, and the typical HRCT findings of ground-glass opacity, reticulation, honeycombing, or combinations thereof that characterise ILD.
What unites ILD conditions is this common anatomical target and this common functional consequence. What distinguishes them is their cause, their mechanism, their distribution within the lung, their natural history, and — critically for patients — their response to treatment.
The ILD Family — Major Categories and Their Causes
ILDs are classified into four main categories based on their cause, though the boundaries between categories are not always sharp and many patients present with features of more than one type.
Idiopathic Interstitial Pneumonias — When No Cause Is Found
The largest and most clinically significant category of ILD comprises the idiopathic interstitial pneumonias (IIPs) — conditions in which the lung damage has no identifiable external cause, arising from processes within the lung itself that remain incompletely understood. Several subtypes are recognised, distinguished primarily by their HRCT pattern and histological appearance.
Idiopathic Pulmonary Fibrosis (IPF) is the most common and most serious IIP. It produces a specific pattern called UIP (usual interstitial pneumonia) — characterised by basal and subpleural honeycombing and reticulation on HRCT — and follows a progressively declining course that does not respond to immunosuppressive therapy. It predominantly affects men over 60 with a smoking history. Antifibrotic drugs (nintedanib and pirfenidone) slow the rate of progression and are the cornerstone of modern IPF management.
Non-Specific Interstitial Pneumonia (NSIP) is the second most common IIP and carries a significantly better prognosis than IPF. It produces a more homogeneous ground-glass opacity pattern predominantly in the lower lobes and is associated with connective tissue diseases in a significant proportion of patients. Unlike IPF, NSIP often responds to immunosuppressive therapy — making the distinction between UIP and NSIP patterns on HRCT one of the most clinically consequential radiological interpretations in pulmonology.
Cryptogenic Organising Pneumonia (COP) produces consolidation — areas of lung that appear solid rather than air-filled — in a patchy, migratory pattern that frequently mimics pneumonia radiologically. It is one of the most responsive forms of ILD to corticosteroid treatment, with many patients achieving complete resolution. Failure to respond to antibiotics in a patient with "recurrent pneumonia" that migrates to different areas of the lung should prompt consideration of COP.
Respiratory Bronchiolitis-ILD and Desquamative Interstitial Pneumonia (DIP) are smoking-related ILDs that may substantially improve or resolve with smoking cessation — making the identification of smoking as the cause particularly important in these patients.
ILD Associated With Connective Tissue Disease
Connective tissue diseases (CTDs) — including rheumatoid arthritis, systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), Sjögren's syndrome, polymyositis/dermatomyositis, and mixed connective tissue disease — commonly involve the lungs, producing ILD as a major complication in a significant proportion of affected patients. CTD-associated ILD is an important category in Pakistan, where rheumatological conditions are prevalent and frequently underdiagnosed or undertreated.
Systemic sclerosis carries the highest ILD burden of any CTD — ILD develops in up to 70 percent of scleroderma patients, and pulmonary complications (including ILD and pulmonary hypertension) are the leading cause of scleroderma-related mortality. The ILD of scleroderma most commonly follows an NSIP pattern and may respond to immunosuppressive therapy including mycophenolate mofetil and nintedanib, which has specific regulatory approval for this indication.
CTD-ILD differs from idiopathic ILD in an important way: the underlying autoimmune process is the driver of lung injury, and treating the systemic disease — with appropriate rheumatological management — is a critical component of managing the lung disease. A patient with CTD-ILD managed by a pulmonologist alone, without rheumatological co-management, is not receiving optimal care.
ILD With Identifiable Environmental or Occupational Cause
Several ILDs result from identifiable environmental or occupational exposures that, when identified and removed, can produce substantial improvement or halt further progression. This category represents the most potentially reversible group of ILDs — making the exposure history the most important investigation. Key conditions in this category include:
- Hypersensitivity pneumonitis — caused by inhaled organic antigens (bird proteins, mould spores, agricultural dusts). Detailed discussion in a dedicated article in this series. Early identification of the causative antigen and complete avoidance is the most important intervention, producing excellent outcomes when implemented before chronic fibrosis develops.
- Pneumoconioses — silicosis, coal workers' pneumoconiosis, asbestosis — caused by inorganic mineral dust inhalation in occupational settings. These conditions are irreversible once established, making primary prevention through dust control the most important management. Also discussed in detail in the occupational lung disease article in this series.
- Drug-induced ILD — a growing and increasingly recognised category, as many commonly prescribed medications can cause ILD in susceptible individuals. Methotrexate, amiodarone, nitrofurantoin, bleomycin, and numerous targeted cancer therapies and immunotherapy agents are among the most important culprits. Drug-induced ILD is frequently missed because the lung abnormalities are attributed to infection or progression of the underlying condition for which the drug was prescribed — rather than to the drug itself. Recognising and stopping the causative medication is the primary treatment.
ILD in Specific Systemic Conditions
Several systemic conditions cause ILD as part of their multiorgan involvement. Sarcoidosis — covered in detail in a dedicated article in this series — is the most common in this category, producing granulomatous inflammation in the lung parenchyma and mediastinal lymph nodes that can lead to fibrosis in a minority of patients. Langerhans cell histiocytosis, lymphangioleiomyomatosis (LAM) — a rare condition predominantly affecting young women — and amyloidosis are other, less common members of this group.
Recognising ILD — The Symptoms
The most consistent symptom across all ILD subtypes — initially noticed only on significant exertion, gradually occurring with less activity. The gradual onset makes it easy to normalise as ageing or deconditioning. Any progressive reduction in exercise tolerance over months warrants spirometry and HRCT evaluation.
A dry, irritating cough — not productive of significant sputum — is present in the majority of ILD patients. It reflects irritation of the inflamed or fibrotic alveolar lining rather than airway disease, which is why bronchodilator inhalers typically provide little relief — an important clinical clue distinguishing ILD cough from asthma or COPD cough.
Fine, dry crackles at the lung bases — heard with a stethoscope and sounding like Velcro being pulled apart — are one of the most important clinical findings in ILD. They reflect the opening of fibrotic or inflamed alveoli with each breath. Their presence in a patient with progressive breathlessness and dry cough should always prompt HRCT evaluation.
Rounding and broadening of the fingertip nail beds — finger clubbing — is present in approximately 50 percent of IPF patients and is a recognised feature of several fibrotic ILDs. Its presence in a patient with progressive breathlessness and dry cough should significantly raise the index of suspicion for ILD and prompt specialist evaluation.
A profound fatigue — reflecting the increased work of breathing through stiff, scarred lungs and the reduced oxygen delivery from impaired gas transfer — significantly impairs quality of life and daily function. This fatigue is often underestimated by clinicians and under-reported by patients who attribute it to ageing.
Blue discolouration of the lips or fingertips — and oxygen saturation below 94 percent at rest or dropping during exertion — indicate that gas transfer impairment has reached a clinically significant level. Exertional desaturation — oxygen saturation dropping with walking — can precede resting desaturation by years and should be specifically assessed with a six-minute walk test and pulse oximetry in ILD patients.
The patients I worry most about in ILD are the ones who have adapted so thoroughly to their breathlessness that they no longer recognise how limited they are. They stopped climbing stairs — so they do not feel breathless on stairs. They stopped walking to the shops — so they do not feel breathless walking. They describe themselves as "fine" because their adapted life no longer challenges their diminished lung capacity. When I do a six-minute walk test, the objective evidence tells a different story. ILD patients should be assessed objectively — not simply asked how they are feeling.
— Dr. Nabila Zaheer, Pulmonologist
Diagnosing ILD — A Multidisciplinary Process
The diagnosis of ILD — and specifically the diagnosis of which type of ILD — is one of the most complex processes in pulmonary medicine. It typically requires integration of clinical history, exposure history, serological testing, pulmonary function testing, HRCT imaging, and in many cases tissue biopsy, interpreted together by a multidisciplinary team (MDT) including a pulmonologist, radiologist, rheumatologist where relevant, and pathologist.
Clinical and Exposure History
The history provides the diagnostic framework within which all investigations are interpreted. Key questions include: the nature and duration of symptoms; occupation and specific workplace exposures; bird-keeping, agricultural exposures, or domestic mould; medications (current and past, including over-the-counter and herbal preparations); a systematic review of symptoms suggesting connective tissue disease (joint swelling, skin changes, dry eyes or mouth, muscle weakness, Raynaud's phenomenon); family history of lung disease; and smoking history. A thorough exposure and systemic history frequently identifies the cause of ILD — or at minimum substantially narrows the differential — before imaging and investigations are reviewed.
Pulmonary Function Tests
ILD classically produces a restrictive pattern — reduced total lung capacity, reduced FVC, and a preserved or elevated FEV1/FVC ratio. DLCO is characteristically reduced, often disproportionately to the spirometric impairment, reflecting the specific impairment of gas transfer across thickened alveolar walls that is the functional signature of ILD. The severity of DLCO reduction correlates broadly with the extent of fibrotic involvement and is used as a monitoring tool for disease progression. A six-minute walk test with pulse oximetry quantifies functional exercise capacity and documents exertional desaturation — a marker of severity that is not captured by resting pulmonary function tests.
High-Resolution CT (HRCT) — The Most Important Imaging Investigation
HRCT of the chest is the cornerstone of ILD investigation. It characterises the pattern of lung involvement in a way that a chest X-ray cannot, and experienced radiologists can identify the specific ILD pattern with sufficient confidence to guide management in many cases without proceeding to biopsy.
The major HRCT patterns in ILD and their associated diagnoses:
- UIP pattern (honeycombing and reticulation predominantly in the bases and subpleural areas) — most commonly IPF; also seen in CTD-ILD and chronic HP
- NSIP pattern (homogeneous ground-glass opacity and reticulation, lower lobe predominant, subpleural sparing) — most commonly associated with CTD-ILD or idiopathic NSIP
- Ground-glass opacity with centrilobular nodules and mosaic attenuation — characteristic of subacute hypersensitivity pneumonitis
- Consolidation in a peribronchial and subpleural distribution — characteristic of cryptogenic organising pneumonia
- Perilymphatic nodules with bilateral hilar lymphadenopathy — characteristic of sarcoidosis
- Upper lobe fibrosis with irregular cystic spaces — characteristic of Langerhans cell histiocytosis or silicosis
Blood Tests and Autoimmune Serology
A comprehensive blood test panel for ILD includes: antinuclear antibody (ANA), anti-dsDNA, anti-Scl70, anti-centromere, anti-Ro/La (Sjögren's), anti-Jo-1 and myositis-specific antibodies (inflammatory myopathy), rheumatoid factor and anti-CCP (rheumatoid arthritis), and ANCA (vasculitis) — to identify connective tissue disease as an underlying cause. Serum precipitins for bird and agricultural antigens identify hypersensitivity pneumonitis. ACE level, calcium, and LDH support a sarcoidosis diagnosis. KL-6 — a glycoprotein marker of alveolar epithelial damage — is elevated in active ILD and can serve as a monitoring biomarker in some patients.
Bronchoalveolar Lavage (BAL)
BAL — obtaining a fluid sample from the alveolar surface by instilling and recovering saline through a bronchoscope — provides cellular analysis that supports specific ILD diagnoses. An elevated lymphocyte count suggests sarcoidosis, HP, or COP. An elevated eosinophil count raises the possibility of eosinophilic pneumonia. Haemosiderin-laden macrophages indicate alveolar haemorrhage. The CD4:CD8 lymphocyte ratio distinguishes sarcoidosis (high ratio) from HP (low ratio) — an important differential in the Pakistani context where both conditions are common and frequently confused.
Surgical Lung Biopsy and Transbronchial Cryobiopsy
When HRCT appearances are insufficient to confidently diagnose the ILD subtype — and the distinction between subtypes has meaningful treatment implications — tissue biopsy is required. Video-assisted thoracoscopic surgery (VATS) surgical lung biopsy has traditionally been the gold standard, providing large, well-preserved tissue samples from multiple lobes. Transbronchial cryobiopsy — a newer technique in which a cryoprobe passed through a bronchoscope freezes and removes a larger airway tissue sample than conventional forceps biopsy — is increasingly used as a less invasive alternative with diagnostic yields approaching those of surgical biopsy in experienced centres.
The Multidisciplinary Discussion — Why It Matters
The diagnosis of ILD subtype is, in many cases, not straightforwardly determined by any single investigation. The HRCT pattern may be characteristic of one condition but consistent with another. The biopsy findings may show features of multiple patterns. The clinical history provides context that changes the interpretation of the imaging. For these reasons, the definitive ILD diagnosis is ideally established through a multidisciplinary team discussion — where a pulmonologist, radiologist experienced in thoracic imaging, and pathologist review all available information together.
Studies consistently show that MDT discussion changes the diagnosis in 20 to 40 percent of ILD patients compared to the diagnosis reached by any individual specialist alone — demonstrating that the MDT is not a bureaucratic process but a genuine diagnostic tool that improves accuracy. For patients, this means that a provisional ILD diagnosis made by a single clinician — based on one investigation — may not be the final or most accurate diagnosis, and that access to specialist MDT review is worth seeking.
Treatment — Matched to the Specific ILD Type
The treatment of ILD is entirely dependent on the specific subtype — which is the primary reason why accurate diagnosis is so critical. Treating IPF with immunosuppressants — which are actually harmful in this condition — while withholding antifibrotics would be a serious management error that worsens rather than improves outcomes. Treating NSIP with antifibrotics when it would have responded to immunosuppression misses the opportunity for a much better response. The diagnosis drives the treatment, and the treatment drives the outcome.
Idiopathic pulmonary fibrosis is treated with antifibrotic drugs — nintedanib or pirfenidone — which slow the rate of lung function decline by approximately 50 percent compared to placebo in clinical trials. They do not reverse existing fibrosis or cure the disease, but they meaningfully extend the time to significant deterioration and to the need for transplant consideration. Immunosuppressive drugs are specifically contraindicated in IPF — a landmark clinical trial (PANTHER-IPF) showed that the combination of prednisolone, azathioprine, and N-acetylcysteine — previously a standard treatment — actually increased mortality in IPF patients compared to placebo. This counterintuitive finding underscores the critical importance of distinguishing IPF from other fibrotic ILDs where immunosuppression is beneficial.
NSIP — whether idiopathic or associated with connective tissue disease — responds to immunosuppressive therapy in a significant proportion of patients. Oral corticosteroids are typically the initial treatment, with mycophenolate mofetil or azathioprine used as steroid-sparing agents for long-term maintenance. For CTD-ILD specifically, mycophenolate mofetil and cyclophosphamide have the strongest evidence base. Nintedanib has received regulatory approval for progressive ILD associated with systemic sclerosis and is used in CTD-ILD patients whose disease continues to progress despite immunosuppression. Rituximab — an anti-B-cell biological therapy — is increasingly used for refractory cases, particularly in inflammatory myopathy-associated ILD.
COP is one of the most treatment-responsive forms of ILD. Oral prednisolone — typically 0.75 to 1 mg/kg/day — produces dramatic improvement in most patients within two to four weeks, with radiological resolution often complete within months. The challenge with COP is the high relapse rate when steroids are tapered too quickly — a prolonged tapering course over six to twelve months significantly reduces relapse risk. Patients who relapse on steroid reduction usually respond again to dose increase.
The cornerstone of HP treatment is complete and permanent removal from the causative antigen — as discussed in the dedicated HP article in this series. In acute and subacute HP where inflammatory activity predominates over established fibrosis, corticosteroids accelerate resolution after antigen removal. In chronic fibrotic HP, antifibrotic therapy (nintedanib or pirfenidone) can be considered for progressive disease following the principles of progressive fibrotic ILD management.
The primary treatment for drug-induced ILD is identification and discontinuation of the causative medication. This requires careful review of all medications — including those started months or years before ILD presentation, as drug-induced ILD can have a prolonged latency. Corticosteroids may accelerate recovery in significant cases. Close monitoring is essential after drug withdrawal, as not all drug-induced ILDs fully resolve even after the offending medication is stopped.
A recent and clinically significant development is the recognition of "progressive fibrosing ILD" (PF-ILD) as a treatment category — encompassing patients with various ILD subtypes (NSIP, HP, CTD-ILD, unclassifiable ILD) whose disease continues to progress despite specific treatment. Nintedanib has demonstrated benefit in reducing lung function decline in PF-ILD regardless of the underlying ILD subtype, and is increasingly used across this heterogeneous group of patients with progressive fibrotic disease.
Across all ILD subtypes, supportive measures improve quality of life independently of disease-modifying treatment: long-term oxygen therapy for persistent hypoxaemia; pulmonary rehabilitation to improve exercise capacity and reduce breathlessness; treatment of comorbid conditions including gastro-oesophageal reflux (associated with IPF progression), pulmonary hypertension (a common complication of advanced ILD), and depression and anxiety; cough suppression with low-dose oral corticosteroids, thalidomide, or opioids in selected patients; and palliative care involvement for patients with advanced disease to address symptom burden, psychosocial needs, and end-of-life preferences.
Monitoring — Why ILD Requires Long-Term Specialist Follow-Up
ILD — regardless of subtype — requires ongoing specialist monitoring. The goals of monitoring are to track disease trajectory (whether stable, improving, or declining), to detect complications early (pulmonary hypertension, respiratory infections, acute exacerbations), to adjust treatment as disease activity changes, and to ensure that the specific ILD diagnosis is reassessed if the clinical course deviates from what the initial diagnosis would predict.
Standard monitoring at regular intervals — typically every three to six months in active or changing disease, every six to twelve months in stable disease — includes spirometry and DLCO, assessment of breathlessness and functional status, a six-minute walk test with oximetry, pulse oximetry at rest and during exertion, and periodic HRCT where clinical change warrants reimaging. KL-6 measurement where available provides an additional biomarker of alveolar epithelial activity. Echocardiography is performed periodically to screen for developing pulmonary hypertension.
The most common management error I see in ILD outside specialist centres is the assumption that a stable initial assessment means no further monitoring is needed. ILD can progress silently — lung function declining on serial measurements while the patient remains apparently stable symptomatically, because they have adapted their activity level to their reduced capacity. Regular objective monitoring — spirometry, DLCO, walk test — is what captures this progression before it becomes clinically catastrophic. Stability today does not guarantee stability next year. ILD needs consistent, long-term specialist attention.
— Dr. Nabila Zaheer, Pulmonologist
Frequently Asked Questions
I have been told I have "interstitial changes" on my CT. Does that mean I have ILD?
Not necessarily — and this is an important distinction. "Interstitial changes" on a CT report is a descriptive finding, not a diagnosis. Minor interstitial changes — particularly in older adults — can represent normal ageing-related changes, post-inflammatory scarring from previous respiratory infections, or incidental findings of uncertain significance. Clinically significant ILD requires not just imaging findings but a clinical context — symptoms, functional impairment on pulmonary function tests, and a pattern of change consistent with a specific ILD subtype. A finding of interstitial changes on a CT warrants specialist pulmonology review to determine whether it represents true ILD requiring monitoring and treatment, or an incidental finding that requires only periodic reassurance. Do not assume the worst from descriptive imaging language without specialist interpretation.
My doctor says I have pulmonary fibrosis. Is that the same as IPF?
No — and this distinction is critically important for treatment decisions. Pulmonary fibrosis is a descriptive term meaning scar tissue formation in the lung — it is the common final pathway of many different ILD subtypes. IPF (idiopathic pulmonary fibrosis) is a specific ILD subtype defined by the UIP pattern on HRCT and the absence of an identifiable cause, carrying a specific prognosis and requiring specific antifibrotic treatment. Fibrosis from hypersensitivity pneumonitis, sarcoidosis, connective tissue disease, or drug reaction may appear similar on imaging but have different causes, different natural histories, and different treatment approaches. If you have been told you have "pulmonary fibrosis" without a more specific subtype diagnosis, please ask your pulmonologist whether the specific type has been established — and if not, request specialist ILD multidisciplinary review to reach a more precise diagnosis.
Can ILD be cured?
It depends entirely on the type. Cryptogenic organising pneumonia — one of the most common and most responsive ILD subtypes — often achieves complete radiological and functional resolution with corticosteroid treatment, constituting effective cure in many cases. Hypersensitivity pneumonitis, when diagnosed before chronic fibrosis develops and the causative antigen is completely removed, can fully resolve. Drug-induced ILD frequently resolves after stopping the causative medication. NSIP and CTD-ILD can achieve sustained remission with immunosuppressive treatment. IPF, by contrast, is not currently curable — antifibrotics slow progression but do not reverse established fibrosis. This range — from fully reversible to incurable but manageable — is one of the most important reasons that accurate specific ILD diagnosis changes everything about the treatment conversation.
I have rheumatoid arthritis and have just been told I have ILD. How are they related?
Rheumatoid arthritis (RA) is associated with lung involvement in up to 30 percent of patients, and ILD is the most serious pulmonary manifestation of RA. RA-ILD can present as a UIP pattern (similar to IPF) or an NSIP pattern, and distinguishing between these carries significant treatment implications — UIP-pattern RA-ILD may benefit from antifibrotic therapy, while NSIP-pattern RA-ILD is more likely to respond to immunosuppression. The management of RA-ILD requires coordination between your rheumatologist and pulmonologist — because the treatment of the RA itself (disease-modifying drugs) and the treatment of the ILD must be considered together, and some RA medications (notably methotrexate) can themselves cause drug-induced ILD that mimics RA-ILD. A joint rheumatology-pulmonology assessment is the ideal approach.
How quickly does ILD progress? Should I be worried about rapid deterioration?
This varies enormously between ILD subtypes and between individual patients — and this variability is one of the most important reasons that ILD requires personalised specialist management rather than general guidance. Some ILD subtypes — particularly IPF — can follow a highly variable course: stable for years then experiencing a sudden acute exacerbation with rapid deterioration. Others — like NSIP — typically follow a more gradual, predictable decline. The rate of decline in the first six to twelve months after diagnosis is one of the strongest predictors of future trajectory for most ILD subtypes. Patients who have stable or improving lung function in the first year generally have a better prognosis than those who show early decline. This is why baseline and six-monthly pulmonary function tests are so important — not just to characterise current status, but to establish the individual trajectory that guides treatment decisions.
An ILD Diagnosis Is Not an Answer — It Is the Beginning of the Right Questions.
If you have been told you have interstitial lung disease, pulmonary fibrosis, or interstitial changes on a scan — and you do not yet have a specific subtype diagnosis, a clear understanding of the cause, and a treatment plan matched to that specific diagnosis — book a consultation with Dr. Nabila Zaheer at PulmoCare today. The right diagnosis makes all the difference.
Book an Appointment